Citalopram用於憂鬱症患者之臨床療效評估：前趨研究

Efficacy of Citalopram in Major Depression Outpatient: A Pilot Study

黃俊仁(Chun-Jen Huang) ； 李維仁(Wei-Jen Lee) ； 秦文鎮(Wen-Cheng Chin) ； 蘇清泉(Ching-Chyuan Su)

《東港安泰醫護雜誌》 11卷2期 (2005/06) Pp. 79-86

https://doi.org/10.7078/TSMHMNJ.200506.0079

摘要

Citalopram是一個新型的血清素再回收抑制劑，在許多臨床實驗中被證明具有優越的抗憂鬱效果，Citalopram相較其他血清素再回收抑制劑具有以下特色:對血清素再回收之選擇性最高、藥效起始時間最快、具有優越的藥物動力學、對於肝臟酵素P-450的影響最小。在本實驗中我們讓14位憂鬱症患者服用Citalopram，為期六週，評估本品對亞洲人種的療效與耐受性，結果顯示Citalopram明顯改善了漢氏量表分數與臨床整體評估分數，在副作用方面，僅有少部分患者出現輕微的胃腸道與中樞神經的副作用，顯示本品有良好的耐受性。

關鍵字

Citalopram ； 憂鬱症 ； 療效

並列摘要

Citalopram was the latest selective serotonin reuptake inhibitor (SSRI) and had be demonstrated to approve for treatment of depression in many clinical trials. The features of citalopram are different from other SSRIs. It is the most selective and earliest onset of the SSRIs and has a favorable pharmacokinetic profile and minimal effects on cytochrom P450 isoenzyme system. In our six weeks study, fourteen Asiatic patients with depressive disorder were treated citalopram and evaluated their efficacy and tolerance. The results of this study indicate that citalopram has significant improvement in both Hamilton rating scores for depression and Clinical Global Impression scale. On the other hand, citalopram only induced fewer gastrointestinal and central adverse events to show its excellent tolerability.

並列關鍵字

Citalopram ； Major Depression ； Efficacy